Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/9182
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rayner, C. | - |
dc.contributor.author | Hart, A. | - |
dc.contributor.author | Hayward, C. | - |
dc.contributor.author | Emmanuel, A. | - |
dc.contributor.author | Kamm, M. | - |
dc.date.issued | 2004 | - |
dc.identifier.citation | Alimentary Pharmacology and Therapeutics, 2004; 20(1):65-71 | - |
dc.identifier.issn | 0269-2813 | - |
dc.identifier.issn | 1365-2036 | - |
dc.identifier.uri | http://hdl.handle.net/2440/9182 | - |
dc.description | The definitive version is available at www.blackwell-synergy.com | - |
dc.description.abstract | Background: Forty per cent of patients with inflammatory bowel disease fail to respond to standard dose azathioprine (2 mg/kg/day). Aims: To evaluate the efficacy and safety of increasing the azathioprine dose according to a fixed schedule and guided by clinical response and adverse effects.Methods: We reviewed the records of all patients with inflammatory bowel disease treated by a single clinician over 6 years, unresponsive to at least 3 months treatment with standard dose azathioprine, and whose dose was subsequently increased. Results: Forty patients (27 male; 24 Crohn's, 16 ulcerative colitis) with chronic active disease or recurrent flares despite standard dose azathioprine for a median 8 months (range 3–114) increased their dose from a median 2.02 (1.61–3.19) mg/kg/day to 2.72 (2.37–3.99) mg/kg/day in one to four increments of 0.5 mg/kg/day, and were followed over a median6 (0.5–54) months. Eleven of the 40 patients (seven Crohn's, four ulcerative colitis) responded or had reduced frequency of flare-ups at the end of follow-up, while 17 of the 40 patients had no benefit. Response was more likely for maximum doses ≤2.5 mg/kg/day (six of 11 patients) than for doses >2.5 mg/kg/day (five of 29 patients) (P = 0.042). Twelve patients (11 of whom received maximum doses >2.5 mg/kg/day) were unable to maintain an increased azathioprine dose because of leukopenia in eight, nausea in three, and raised liver enzymes in one (all transient and reversible). Conclusions: Increasing the azathioprine dose up to 2.5 mg/kg/day appears beneficial in patients who have not responded to 2 mg/kg/day. Further increase above 2.5 mg/kg/day is less likely to be efficacious, and is associated with a substantial risk of adverse reactions. | - |
dc.description.statementofresponsibility | C.K. Rayner, A.L. Hart, C.M.M. Hayward, A.V. Emmanuel & M.A. Kamm | - |
dc.language.iso | en | - |
dc.publisher | Blackwell Publishing Ltd | - |
dc.source.uri | http://dx.doi.org/10.1111/j.1365-2036.2004.02009.x | - |
dc.subject | Humans | - |
dc.subject | Colitis, Ulcerative | - |
dc.subject | Crohn Disease | - |
dc.subject | Azathioprine | - |
dc.subject | Immunosuppressive Agents | - |
dc.subject | Treatment Outcome | - |
dc.subject | Retrospective Studies | - |
dc.subject | Drug Evaluation | - |
dc.subject | Dose-Response Relationship, Drug | - |
dc.subject | Adult | - |
dc.subject | Middle Aged | - |
dc.subject | Female | - |
dc.subject | Male | - |
dc.title | Azathioprine dose escalation in inflammatory bowel disease | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1111/j.1365-2036.2004.02009.x | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Rayner, C. [0000-0002-5527-256X] | - |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.